U.S. Osteonecrosis Market - Industry Trends and Forecast to 2030
U.S. osteonecrosis market is expected to reach USD 843,039.67 thousands by 2030 from USD 535,723.00 thousands in 2022, growing at a CAGR of 5.9% during the forecast period of 2023 to 2030.
Market SegmentationU.S. Osteonecrosis Market , By Disease Type (Traumatic, Non-Traumatic, And Idiopathic), Type (Diagnosis, and Treatment), Stages (Stage1, Stage2, Stage3, and Stage4), Location (Osteonecrosis Of Hip/Femoral Head Osteonecrosis, Osteonecrosis Of The Knee, Osteonecrosis Of The Shoulder, Osteonecrosis Of The Talus, Osteonecrosis Of The Lunate, Osteonecrosis Of The Scaphoid, and Others), Drug Type (Branded and Generic), Prescription (Over The Counter Drugs, and Prescribed Drugs), Gender (Male and Female), Age (Children, Adult, and Geriatric) End User (Hospitals, Specialty Clinics, Orthopaedic Clinics, Ambulatory Centers, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030
Overview of U.S. Osteonecrosis Market Dynamics
Driver• Increasing number of traumatic injuries
Restraint• High cost associated with the diagnosis and treatment of osteonecrosis
Opportunity• Advancements in medical technology for osteonecrosis
Market PlayersSome of the key market players operating in the U.S. osteonecrosis market are listed below
• Sciegen Pharmaceuticals
• Almatica Pharma
• Dr. Reddy's Laboratories Ltd.
• Bayer AG
• Pfizer Inc.
• Haleon Group of Companies
• Zimmer Biomet
• Stryker
• Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.)
• Arthrex, Inc
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. These report will take approximately 15-20 business days to prepare and deliver.